Chief Scientific Officer
Uwe Gottschalk is Chief Scientific Officer (CSO) at Lonza since July 2017. Between 2014 and 2017 he served as a Chief Technology Officer where he established and led the global Research and Technology organisation of Lonza Pharma/Biotech.
Before joining Lonza he served as Group Vice President at Sartorius Stedim Biotech between 2004 and 2014 with a global responsibility for all bioseparation-related process technology. He worked in different capacities for Bayer Health Care from 1991 to 2004, overseeing the process development and manufacturing of biopharmaceutical products such as monoclonal antibodies and other recombinant proteins.
Uwe earned his M.Sc and PhD in Chemistry at the University of Münster, Germany and Nottingham, UK, delivering his dissertation on drug targeting with monoclonal antibodies. He has written extensively in the areas of downstream processing, industrial biotechnology and somatic gene therapy. In academia, Dr. Gottschalk is currently Head Lecturer at the University of Duisburg-Essen (Germany) and also lectured at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Lausanne (Switzerland).
Dr. Gottschalk was board member of the VBU Association of German Biotech Companies between 2006 and 2010. He sits on the editorial advisory boards of Pharmaceutical Bioprocessing, Genetic Engineering News and BioPharm International. He is honorary member of the Society for BioChromatography and Nanoseparations, member of the Management Pool at the Institut of Marketing, University of St. Gallen (HSG) and member of the American Chemical Society (ACS).